Strongbridge Biopharma: Commercial stage;focused on rare diseases with significant unmet needs. Endocrine franchise includes RECORLEV™, cortisol synthesis inhibitor in Ph 3 for endogenous Cushing's syndrome, and veldoreotide, next-gen somatostatin analog for acromegaly. Neuromuscular franchise includes KEVEYIS® approved for primary periodic paralysis. Company sold NA rights for MACRILEN™ to Novo Nordisk for $145 m upfront and tiered royalties in Oct 2018.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Marketed
Disease Space
Central Nervous System, Rare Disease
Finance
Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Address:
900 Northbrook Dr #200
Feasterville Trevose, PA 19053
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.